Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

  1. García-Alfonso, P.
  2. Benavides, M.
  3. Falcó, E.
  4. Muñoz, A.
  5. Gómez, A.
  6. Sastre, J.
  7. Rivera, F.
  8. Montagut, C.
  9. Salgado, M.
  10. López-Ladrón, A.
  11. López, R.
  12. Ruiz de Mena, I.
  13. Durán, G.
  14. Aranda, E.
Journal:
Oncologist

ISSN: 1549-490X 1083-7159

Year of publication: 2018

Volume: 23

Issue: 11

Pages: 1271-e128

Type: Article

DOI: 10.1634/THEONCOLOGIST.2018-0316 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals